上皮中性粒细胞活化肽78重组兔单抗
Rrmab®兔单抗
货号：bsm-62331R
产品详情
相关标记
相关产品
相关文献
常见问题
概述
产品编号
bsm-62331R
产品类型
重组兔单抗
英文名称
CXCL5 Recombinant Rabbit mAb
中文名称
上皮中性粒细胞活化肽78重组兔单抗
英文别名
ENA-78; SCYB5; AMCF-II; Cxcl6; GCP-2; LIX; Scyb6; CXCL5_HUMAN; CXCL5; ENA-78(1-78); Epithelial-derived neutrophil-activating protein 78; Neutrophil-activating peptide ENA-78; Small-inducible cytokine B5; ENA78; CXCL5_MOUSE; Cytokine LIX;
抗体来源
Rabbit
免疫原
A synthesized peptide derived from human CXCL5: 75-114
亚型
IgG
性状
Liquid
纯化方法
affinity purified by Protein A
克隆类型
Recombinant
理论分子量
12
检测分子量
10
储存液
10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
研究领域
SWISS
Gene ID
保存条件
Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles.
注意事项
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
数据库链接
背景资料
Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.
产品应用
| 应用 | 已检合格种属 | 预测种属 | 推荐稀释比例 |
|---|---|---|---|
| WB | Human | 1:500-2000 | |
| ICC/IF | Human | 1:50-200 | |
| IP | Human | 1:20-50 |
交叉反应
交叉反应: Human
相关产品
暂无相关产品
靶标
基因名
CXCL5
蛋白名
C-X-C motif chemokine 5
亚细胞定位
Secreted.
翻译后修饰
GCP-2(1-78) and GCP-2(9-78) are produced by proteolytic cleavage after secretion from fibroblasts and epithelial cells. GCP-2(9-78) is the most prominent form. A number of additional N-terminal (processed between pos. 41 and 48) and C-terminal (processed between pos. 118 and 132) processed forms have been identified, probably also representing intermediate states.
相似性
Belongs to the intercrine alpha (chemokine CxC) family.
功能
May participate in the recruitment of inflammatory cells by injured or infected tissue. GCP-2(1-78) and, more potent, GCP-2(9-78) attract neutrophils and are involved in neutrophil activation.
标记抗体
暂无标记数据
同靶标产品
暂无同靶标产品
相关文献
提示: 发表研究结果有使用 bsm-62331R 时请让我们知道，以便我们可以引用参考文章。作为回馈，资料提供者将获得我们送上的小礼品。
暂无相关文献
常见问题
暂无常见问题